Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial

Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, Schem C, Fasching P, Schnappauf B, Karn T, Fehm T, Just M, Kuehn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, Von Minckwitz G, Loges S (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 39

Pages Range: 185-185

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) DE Germany (DE) Universitätsklinikum Düsseldorf DE Germany (DE) Städtische Kliniken Esslingen DE Germany (DE) St. Barbara-Klinik Hamm DE Germany (DE) Klinikum Chemnitz DE Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) HELIOS Kliniken DE Germany (DE) Centrum für Hämatologie und Onkologie Bethanien DE Germany (DE) Luisenkrankenhaus Düsseldorf DE Germany (DE) GBG Forschungs GmbH (German Breast Group) DE Germany (DE)

How to cite

APA:

Janning, M., Mueller, ., Vettorazzi, E., Cubas-Cordova, M., Gensch, ., Ben Batalla, .,... Loges, S. (2016). Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. (pp. 185-185).

MLA:

Janning, M., et al. "Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial." 2016. 185-185.

BibTeX: Download